The androgen receptor: Is it a promising target? Journal Article

  


Authors: Gucalp, A.; Traina, T. A.
Article Title: The androgen receptor: Is it a promising target?
Abstract: A growing body of literature supports the conclusion that the androgen receptor (AR) plays an important role in breast cancer pathogenesis and may prove to be a relevant therapeutic target for patients with AR-driven breast cancer. This has been most apparent in the subset of patients with triple-negative breast cancer (TNBC), in whom approximately 50% of tumors may have androgen dependence. Recent phase 2 clinical trials of agents that antagonize AR or reduce androgen production have shown clinical benefit and efficacy to varying degrees. This review highlights three of these recent trials of AR+ TNBC and acknowledge ongoing research in this exciting area. © 2017, Society of Surgical Oncology.
Journal Title: Annals of Surgical Oncology
Volume: 24
Issue: 10
ISSN: 1068-9265
Publisher: Springer  
Date Published: 2017-10-01
Start Page: 2876
End Page: 2880
Language: English
DOI: 10.1245/s10434-017-5961-9
PROVIDER: scopus
PUBMED: 28766215
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026540684&doi=10.1245%2fs10434-017-5961-9&partnerID=40&md5=f26de1e8c9322befd7b5f42c2313cf0d
Notes: Article -- Export Date: 4 October 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ayca Gucalp
    113 Gucalp
  2. Tiffany A Traina
    250 Traina
Related MSK Work